1 / 11

Dosing could be reduced to 15 mg/day for Tolerability

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder:. Dosing could be reduced to 15 mg/day for Tolerability Aripiprazole : no significant difference from placebo in change in mean body weight

tekli
Télécharger la présentation

Dosing could be reduced to 15 mg/day for Tolerability

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder:

  2. Dosing could be reduced to 15 mg/day for Tolerability • Aripiprazole : no significant difference from placebo in change in mean body weight • not associated with elevated prolactin or QTc prolongation

  3. cholesterol triglycerides low-density lipoprotein (LDL) LDL/HDL, Chol/HDL fasting glucose, fasting insulin insulin resistance index

  4. treatment of an acute manic episode for up to 12 weeks Aripiprazole showed superior levels of response and tolerability to haloperidol

  5. Aripiprazole showed similar efficacy to olanzapine for long-term treatment of acutely psychotic and chronic, stable schizophrenia patients, • lower liability for weight gain or increased lipid levels

  6. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. • daily dose, 16.1 +/- 6.2 mg • body weight: 0.20 +/- 0.09 mg/kg • aripiprazole is likely to be onsidered for obese patients • weight should be considered

  7. short-term treatment of schizophrenia aripiprazole 15-30 mg is as effective haloperidol 10 mg/day risperidone 6 mg/day

  8. Aripiprazole • quinolinone derivative • high affinity for D2 , D3 receptors • partial agonist action on 5-HT (1A) receptors • 5-HT (2A) receptors antagonist

  9. active metabolite: dehydro-aripiprazole, = parent compound dopamine D2 receptors • peak plasma concentration=3 hours • Steady-state plasma concentrations are achieved by 14 days • CYP3A4 and CYP2D6 transform it to dehydroaripiprazole • genetic polymorphism • The drug is effective as early as the first or second week of treatment.

  10. No additional therapeutic benefit at the higher-than-recommended dosages

  11. induce weight gain • clozapine and olanzapine. • TCA, mirtazapine come next • majority of the mood stabilizers. • The old antipsychotics seem to involve less gain of weight. • SSRI make lose weight in the first weeks, but induce a moderate weight gain on the long term.

More Related